中文

新光药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-21
ItemAmountY/Y
Revenue¥0.09B-5.1%
Gross profit¥0.04B
Operating income¥0.03B
Net income¥0.03B+7.4%
Gross margin45.4%Net margin 29.8%
Revenue Q/Q+48.1%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.05B54.6%
R&D¥0.00B3.2%
SG&A¥0.01B9.1%
Tax & other¥0.00B4.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

科大国创爱司凯世名科技辰安科技博思软件ST应急幸福蓝海健帆生物领湃科技优博讯今天国际冰川网络

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies